Betta Pharmaceuticals Co., Ltd.

Overview

Established in 2003, Betta Pharmaceuticals Co., Ltd. is a national high-tech enterprise headquartered in Hangzhou, Zhejiang, China. The company focuses on the research and development of innovative drugs, integrating R&D, manufacturing, and sales. Betta Pharmaceuticals is renowned for its flagship product, Icotinib Hydrochloride (Conmana®), the first innovative small-molecule targeted anti-cancer drug developed and commercially launched by a Chinese pharmaceutical company. Conmana® has achieved significant sales, becoming one of the top-selling targeted therapies for non-small cell lung cancer in China. Betta Pharmaceuticals employs a dedicated research and development team comprising approximately 1,500 researchers, professionals, and technicians. The company has invested over CNY 1.5 billion (approximately USD 230 million) annually into R&D as of 2023. This investment supports the development of innovative therapies, particularly in oncology and autoimmune diseases, underscoring their commitment to advancing healthcare solutions. The company's intellectual property portfolio includes numerous patents, with sales from patented products accounting for a significant portion of its total revenue. In addition to its domestic achievements, Betta Pharmaceuticals has engaged in strategic partnerships to expand its global presence. Notably, in July 2020, Betta Pharmaceuticals invested $20 million in Agenus Inc., a U.S.-based immuno-oncology company, as part of a broader partnership to develop and commercialize cancer therapies in Greater China. This investment highlights Betta Pharmaceuticals' commitment to advancing global healthcare through strategic collaborations and investments in innovative biopharmaceutical companies.

Investment Focus

• Focus on innovative oncology therapies
• Preference for early to late-stage investments
• Interest in both domestic and international collaborations

Portfolio Companies